ALXN Alexion Pharmaceuticals, Inc.

118.83
+0  (0%)
Previous Close 118.35
Open 118.35
Price To book 3.05
Market Cap 26.69B
Shares 224,613,000
Volume 1,525,453
Short Ratio 1.71
Av. Daily Volume 1,929,700

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2017.
Eculizumab
Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase 3 enrollment to be completed 2017; expects to initiate a Phase 3 trial in pediatric patients 2Q 2017.
ALXN1210
atypical Hemolytic Uremic Syndrome (aHUS)
Phase 3 enrollment commenced 4Q 2016. Enrollment to be completed 2017.
ALXN1210
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 2/3 enrolling.
ALXN1101
Molybdenum cofactor deficiency (MoCD) Type A
Phase 1/2 ongoing. 6 and 12 month data due 2017.
SBC-103
MPS IIIB
(sBLA) PDUFA date October 23, 2017.
Eculizumab
Refractory generalized myasthenia gravis (gMG)